Ambirix Vaccine Description
Ambirix contains inactivated (killed) hepatitis A virus and ‘surface antigen’ (proteins from the surface) parts of the hepatitis B virus as active substances.
These vaccines are used to protect against the same diseases, but Twinrix is given as a three-dose schedule, whereas Ambirix is given as 2 injections 6 to 12 months apart.
Protection against hepatitis B infections may not be obtained until after the second dose.
Ambirix is a registered trademark of the GlaxoSmithKline Group of Companies.
Ambirix Vaccine Indication
Ambirix is indicated in non-immune children and adolescents from 1 year up to and including 15 years of age for protection against hepatitis A and hepatitis B infection.
Ambirix should be used only when there is a relatively low risk of hepatitis B infection during the vaccination course.
Ambirix Vaccine Dosage
It is recommended that Ambirix be administered in settings where completion of the two-dose vaccination course can be assured. A dose of 1.0 ml is recommended for subjects from 1 year up to and including 15 years of age.
The standard primary course of vaccination consists of two doses, the first administered at the selected date and the second between 6 and 12 months after the first dose.
The recommended schedule should be adhered to. Once initiated, the vaccination's primary course should be completed with the same vaccine.